Drugs / Desirudin
Desirudin
also known as
63-desulfohirudin · 63-desulfohirudin (recombinant) · CGP 39393 · Desirudin recombinant · Desirudina · Desirudine · Hirudin desirudin · Iprivask · +1 more
Protein / enzyme biologic targets F2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Revasc | — | 2014-07-18 | europa.eu ↗ |
| Approved | EU (EMA) | Revasc | — | 1997-07-09 | europa.eu ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT00329433 | May 2006 → Oct 2008 | venous thromboembolism | Washington University School of Medicine | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT00913133 | Mar 2010 → Jun 2011 | thrombotic disease | Canyon Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00787332 | Sep 2008 → Dec 2009 | heparin-induced thrombocytopenia | Canyon Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Desirudin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00913133 ↗ |
| Known as | 63-desulfohirudin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201662 ↗ |
| Known as | 63-desulfohirudin (recombinant) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201662 ↗ |
| Known as | CGP 39393 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201662 ↗ |
| Known as | Desirudin recombinant | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201662 ↗ |
| Known as | Desirudina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201662 ↗ |
| Known as | Desirudine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201662 ↗ |
| Known as | Hirudin desirudin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201662 ↗ |
| Known as | Iprivask | “Desirudin (Iprivask®, Canyon Pharmaceuticals™) is a recombinant hirudin derivative that directly inhibits free and fibrin-bound thrombin.” PMID 21932952 ↗ Sep 2011 |
| Known as | Revasc | “Desirudin was the first DTI approved for deep vein thrombosis (DVT) prophylaxis in Europe (Revasc®) and is the newest injectable DTI commercially available in the USA.” PMID 21932952 ↗ Sep 2011 |
| Action | Inhibit | “directly inhibits free and fibrin-bound thrombin” PMID 21932952 ↗ Sep 20111“Thrombin inhibitor” CHEMBL1201662 ↗ |
| Modality | Protein / enzyme biologic | “is a recombinant hirudin derivative” PMID 21932952 ↗ Sep 2011 |
| Route | Subcutaneous | “Subcutaneous desirudin has been shown to be more effective than both subcutaneous unfractionated heparin and enoxaparin” PMID 21932952 ↗ Sep 2011 |
| Target | F2 | “Thrombin inhibitor” CHEMBL1201662 ↗ |